- Home
- ADPT vs WSBCO Comparison
ADPT vs WSBCO Comparison
Compare ADPT & WSBCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- WSBCO
- Stock Information
- Founded
- ADPT 2009
- WSBCO N/A
- Country
- ADPT United States
- WSBCO United States
- Employees
- ADPT N/A
- WSBCO N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- WSBCO Major Banks
- Sector
- ADPT Health Care
- WSBCO Finance
- Exchange
- ADPT Nasdaq
- WSBCO Nasdaq
- Market Cap
- ADPT 2.6B
- WSBCO 2.5B
- IPO Year
- ADPT 2019
- WSBCO N/A
- Fundamental
- Price
- ADPT $20.36
- WSBCO $25.75
- Analyst Decision
- ADPT Strong Buy
- WSBCO
- Analyst Count
- ADPT 10
- WSBCO 0
- Target Price
- ADPT $16.60
- WSBCO N/A
- AVG Volume (30 Days)
- ADPT 2.4M
- WSBCO N/A
- Earning Date
- ADPT 11-05-2025
- WSBCO N/A
- Dividend Yield
- ADPT N/A
- WSBCO N/A
- EPS Growth
- ADPT N/A
- WSBCO N/A
- EPS
- ADPT N/A
- WSBCO N/A
- Revenue
- ADPT $252,754,000.00
- WSBCO N/A
- Revenue This Year
- ADPT $36.43
- WSBCO N/A
- Revenue Next Year
- ADPT $12.31
- WSBCO N/A
- P/E Ratio
- ADPT N/A
- WSBCO N/A
- Revenue Growth
- ADPT 42.57
- WSBCO N/A
- 52 Week Low
- ADPT $4.76
- WSBCO N/A
- 52 Week High
- ADPT $20.76
- WSBCO N/A
- Technical
- Relative Strength Index (RSI)
- ADPT 73.37
- WSBCO N/A
- Support Level
- ADPT $13.28
- WSBCO N/A
- Resistance Level
- ADPT $14.24
- WSBCO N/A
- Average True Range (ATR)
- ADPT 1.19
- WSBCO 0.00
- MACD
- ADPT 0.57
- WSBCO 0.00
- Stochastic Oscillator
- ADPT 95.19
- WSBCO 0.00
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).